拉米夫定加肝络欣治疗慢性乙型肝炎疗效及对YMDD变异的影响

观察拉米夫定加肝络欣联合治疗慢性乙型肝炎的疗效及对慢性乙型肝炎病毒P基因(YMDD)变异的影响。收集乙型肝炎病毒(HBV)HBeAg、HBVDNA阳性的慢性乙型肝炎患者6 7例,分为拉米夫定加用肝络欣组(A组)、单用拉米夫定组(B组)。分别检测血清HBeAg、抗-HBe、HBVDNA ,肝脏生化指标和基因YMDD变异。在治疗5 6周时,拉米夫定联合肝络欣组HBeAg/抗-HBe转换率(39. 4 % ) ,优于拉米夫定组(P <0 .0 5 )。HBVDNA阳性率及YMDD变异率都比拉米夫定组低(P <0 . 0 5 )。拉米夫定联合肝络欣能在一定程度上提高治疗慢性乙型肝炎的疗效并可减少YMDD变异。

Therapeutic efficacy of combined application of Lamivudine and Ganluoxin pills in treating chronic hepatitis B and its in fluence on YMDD motif

To observe the effect of combined application of lamivudine and Ganluoxin Pills (GLXP) in treating patients with chronic hepatitis B (CHB) and its influence on YMDD motif. 67 patients of CHB with positive HBeAg and HBVDNA were divided into two groups. Group A treated with lamivudine plus GLXP, group B treated with lami vudine, the serum HBeAg/anti-HBe?HBV-DNA, hepatic biological parameters and YMD D motif mutation were observed. The positive rate of HBeAg/anti-HBe(39.4%)in gr oup A higher than these in group B (P<0.05),the positive rate of HBVDNA and YMDD motif mutation in group A were lower than those in group B respectively after 56 weeks treatment. Combined application of lamivudine and GLXP could enh ance the theraeutic effect in treating CHB to some extent and could reduce the m utation of YMDD motif.